StemRIM (TYO:4599) has amended the protocol for the global late-stage phase two clinical trial of Redasemtide for the treatment of acute ischemic stroke (AIS), according to a Monday filing with the Tokyo Stock Exchange.
The change includes adding a new group of patients who have undergone endovascular recanalization therapy to the study.
The biotechnology company will also relax the eligibility criteria for the participating patients without significantly extending the trial period.
The company said the move aims to address changes in the treatment paradigm for AIS and the rise in the number of eligible patients.
Price (JPY): $345.00, Change: $-5.0, Percent Change: -1.43%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。